 2  8 
Materials and methods
RNA-SEQ and clinical data were downloaded from the TCGA data portal, https://tcga-1 0 8 data.nci.nih.gov/tcga/. For each cancer, survival information was parsed from the 1 0 9 "clinical_follow_up" files and "clinical_patient" file, and for each patient the most recent follow 1 1 0 up information found in the multiple files was kept. Sex, age, and histological grade data were 1 1 1 extracted from the "clinical_patient" file. For each cancer, only patients that had a follow up 1 1 2 time greater than 0 days and had complete clinical information were included in the model. RPKM is simply the reads per kilobase per million mapped reads, while RSEM is a normalized 1 1 5 value outputted by the RSEM software (Li & Dewey 2011) . For each cancer, only genes which 1 1 6 had a median RSEM value greater than 1 (for RNASeqV2), or median RPKM value greater than 1 1 7
.1 (for RNASeq), and had 0 expression in less than one fourth of patients were included in the 1 1 8 analysis. RNASeq uses a different gene annotation file from RNASeqV2, and because 1 1 9
RNASeqV2 represents the most recent analysis, for RNASeq analyses only those genes present 1 2 0 in the RNASeqV2 gene annotation file were included. Multivariate Cox models were run with 1 2 1 the coxph function from the R survival library, and the equation for each model is shown in 1 2 2 Table S1. Grade information was included in the model by separate terms, which were either 1 1 2 3
The values were column scaled to highlight which gene programs are most important for each 3 0 0 cancer. Overall the same groupings that were seen with gene sets and individual genes were The analysis also found cancer specific protective/harmful pathway enrichments that are 3 0 8 consistent with known cancer biology. For example, in KIRC the highest intensity gene program Cancer researchers are increasingly looking to focus on factors which have clinical significance, 3 1 9 and many different resources now allow researchers to identify if a protein of interest has clinical 3 2 0 implications, including OMIM, dbSNP, ClinVar, cBioPortal, FINDbase, and others (Hamosh et   3  2  1 al. 2005; Landrum et al. 2014; Papadopoulos et al. 2014; Smigielski et al. 2000) . Despite this, it 3 2 2 currently is not possible to find comprehensive lists of genes which are associated with survival 3 2 3 in different cancers. Using recently available RNA-SEQ and clinical data from the TCGA for 3 2 4 6,495 patients, we correlated every expressed annotated gene to survival in 16 different cancers, 3 2 5 providing the scientific community with thousands of highly significant genes for further study. There is an unexpectedly large variation between cancers in the number of statistically 3 2 7 significant prognostic genes, which should be used to inform our evaluation of prognostic genes 3 2 8 from different cancers. For example, a significant p-value for a gene from a cancer such as LGG or KIRC should not be surprising, given the thousands of genes that survive a stringent p-value 3 3 0 cutoff in these tumors (Table 1, Fig. 1a, Fig. S1 ). In contrast, weaker p-values for predicting 3 3 1 prognosis in cancers such as STAD or COAD are still biologically important although they have 3 3 2 no genes that pass a stringent p-value threshold for biological significance (Table 1, Fig. 1a, c) . RNA-SEQ is a relatively new technology, and its ability to identify prognostic genes in many 3 3 4 cancers has not been explored. Although the number of expressional level based prognostic which significantly separated patients into high risk and low risk groups. One of the main 3 3 7 advantages of RNA-SEQ over microarrays is the ability to identify unannotated transcripts. In in large numbers of TCGA RNA-SEQ data sets (Han et al. 2014; Iyer et al. 2015) . It would be 3 4 0
interesting to see if these transcripts show the same trends as protein coding genes across these 3 4 1 cancers.
4 2
This comprehensive analysis of prognostic genes allowed us to explore the ability of the 3 4 3 prognostic genes themselves, enriched gene sets, and Cox coefficients (a measure of strength of 3 4 4 correlation to better or worse survival) to identify similarities and differences among cancers. The most prognostically significant genes were not shared between cancers. However, 3 4 6 protective genes and harmful genes are enriched in very different gene sets, and there were large 3 4 7 overlaps of these gene sets for LUAD, LIHC, and KIRP, and for COAD, LUSC, and GBM. The individual genes, and average Cox coefficients of gene programs, suggesting that these findings are biologically significant and that this is an effective strategy for incorporating genomic and Although it is important not to mistake a correlation for causation, the analysis suggests higher than expected (Chiu et al. 2014 ), suggesting that although EGFR itself may not be 3 5 8 mutated, responders may still have a cancer which is dependent on EGFR signaling. This is 3 5 9 consistent with the gene program analysis in this paper, where EGFR response was most strongly 3 6 0 associated with poor survival in LUSC, and LUSC was consistently associated with GBM, which 3 6 1 is a cancer known for EGFR dysreguation. This suggests that using a measure of EGFR activity 3 6 2 other than mutational status could be used to find LUSC patients that would benefit from a 3 6 3 tyrosine kinase inhibitor. In addition, this type of analysis may be used to suggest treatments for there is a current search for drugs which may be of benefit (Schuller et al. 2015) . This analysis 3 6 6
suggests that the pathogenesis of KIRP is very similar to LIHC and LUAD, indicating that 3 6 7 treatments currently used for those cancers may be co-opted for KIRP. This analysis is among the first attempts at using clinical correlations to compare cancers. Although we utilized the most up to date information possible, well established statistical 3 7 0 techniques, and obtained robust findings, there are many ways this type of analysis can be 3 7 1 improved. For example, it is now being recognized that cancer is not a single disease, but rather cancers into four or five subtypes, for example GBM has been divided into proneural, neural, been found for all 16 of the cancers in this study, and for many cancers dividing the cancers into extension of this study would be to repeat it for individual subtypes, which would potentially 3 8 0 decrease the heterogeneity of the data. In addition, treatment is one the largest confounding 3 8 1 variables in survival analyses, but the TCGA pharmacological data is currently incomplete 3 8 2 making it impossible to incorporate this information into the model. Despite these current 3 8 3 limitations, this study has shown that incorporating clinical information into pan-cancer analyses 3 8 4 is capable of yielding insights into cancer pathogenesis that have thus far been unappreciated by 3 8 5 other methods. l  e  y  K  A  ,  Y  a  u  C  ,  W  o  l  f  D  M  ,  C  h  e  r  n  i  a  c  k  A  D  ,  T  a  m  b  o  r  e  r  o  D  ,  N  g  S  ,  L  e  i  s  e  r  s  o  n  M  D  ,  N  i  u  B  ,  M  c  L  e  l  l  a  n  M  D  ,  4  8  0  U  z  u  n  a  n  g  e  l  o  v  V  ,  Z  h  a  n  g  J  ,  K  a  n  d  o  t  h  C  ,  A  k  b  a  n  i  R  ,  S  h  e  n  H  ,  O  m  b  e  r  g  L  ,  C  h  u  A  ,  M  a  r  g  o  l  i  n  A  A  ,  V  a  n  '  t  V  e  e  r  4  8  1  L  J  ,  L  o  p  e  z  -B  i  g  a  s  N  ,  L  a  i  r  d  P  W  ,  R  a  p  h  a  e  l  B  J  ,  D  i  n  g  L  ,  R  o  b  e  r  t  s  o  n  A  G  ,  B  y  e  r  s  L  A  ,  M  i  l  l  s  G  B  ,  W  e  i  n  s  t  e  i  n  J  N  ,  4  8  2  V  a  n  W  a  e  s  C  ,  C  h  e  n  Z  ,  C  o  l  l  i  s  s  o  n  E  A  ,  C  a  n  c  e  r  G  e  n  o  m  e  A  t  l  a  s  R  e  s  e  a  r  c  h  N  ,  B  e  n  z  C  C  ,  P  e  r  o  u  C  M  ,  a  n  d  4  8  3 
